Clinical Trial Update: AAB-001 in Patients With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update for AAB-001 (bapineuzumab) in patients with mild to moderate Alzheimer's disease. The study conducted by Janssen Alzheimer Immunotherapy Re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AAB-001 (bapineuzumab)

Snippet

Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED